Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2606
Abstract: Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid leukemia (CML) patients treated with ponatinib. We identified 85 consecutive CML adult patients who were treated with ponatinib in 17 Italian centers. Patients were stratified… read more here.
Keywords: occlusive events; patients treated; treated ponatinib; myeloid leukemia ... See more keywords
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1261824
Abstract: ABSTRACT Background: A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic… read more here.
Keywords: new generation; generation bcr; occlusive events; bcr abl ... See more keywords
Effects of tranexamic acid on vascular occlusive events and perioperative resuscitation in patients with atrial fibrillation undergoing total joint arthroplasty
Sign Up to like & getrecommendations! Published in 2022 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000002114
Abstract: To the Editor: Tranexamic acid (TXA) has recently become popular for use in orthopedic surgeries owing to its ef fi cacy in reducing blood loss, transfusion rates, and mortality without increasing the risk of deep… read more here.
Keywords: joint arthroplasty; occlusive events; events perioperative; total joint ... See more keywords
Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022008137
Abstract: Key Points • VOE requiring medical care are significantly reduced in patients with SCD after allogeneic transplantation.• The reduction in VOE improves over time, especially beyond 1 year after allogeneic transplantation. read more here.
Keywords: reduction vaso; events following; occlusive events; vaso occlusive ... See more keywords